Human papillomavirus infection: An old disease, a new vaccine

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 3, 2006, Pages 180-185

  Giles, Michelle ^a   Garland, Suzanne ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Cervical cancer; Human papillomavirus; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; CAPSID PROTEIN; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; HYDROXYAPATITE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; WART VIRUS VACCINE;

CLINICAL TRIAL; CONDYLOMA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG FORMULATION; FEMALE; HUMAN; INFECTION PREVENTION; LICENSING; PRIORITY JOURNAL; PUBLISHING; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINIA VIRUS; VIRUS INFECTION; VIRUS PARTICLE; VIRUS RECOMBINANT; VULVA TUMOR; WART VIRUS;

FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 33745943047     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00580.x     Document Type: Review

References (40)

1. AIHW. Cervical Screening in Australia 2002-2003. AIHW Cat. No. 26. Canberra: Australian Institute of Health and Welfare; 2005.
2. Benton C, Shahidullah H, Hunter JAA. Human papilloma virus in the immunosuppressed. Papillomavirus 1992; 3: 23-26.
3. Christensen ND, Reed CA, Cladel NM, Han R, Krelder JW. Immunization with virus-like particles induces long term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 1996; 70: 960-965.
4. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human paipllomavirus 16, L1 virus-like particle vaccine. J Nat Cancer Inst 2001, 93: 284-292.
5. Brown DR, Bryan JT, Schroeder JM et al. Neutralisation of human papillomavirus type 11 (HPV 11) by serum from women vaccinated with yeast derived HPV-11 L1 virus like particles: Correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184: 1183-1186.
6. Evans TG, Bonnez W, Rose RC et al. A phase I study of recombinant viruslike particle vaccine against human papillomavirus type II in healthy adult volunteers. J Infect Dis 2001; 183: 1485-1493.
7. Roden RBS, Greensione HL, Kimbauer R et al. In vitro generation and type-specific neutralisation of a human papillomavirus type 16 virion pseudotype. J Virol 1996; 70: 5875-5883.
8. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-1651.
9. Mao C, Koutsky L, Ault K et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia. A randomised controlled trial. Obstet Gynecol 2006; 107: 18-27.
10. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364: 1757-1765.
11. Villa LL, Costa RL, Petta CA et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278.
12. Skjeldestad F for the FUTURE II Steering Committee, Departmentt of Epidemiology, SINTEF Health Research, Trondheim, Norway. Prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine (Gardasil™) reduces cervical intraepithelial neoplasia (CIN) 2/3 risk. Abstract of the 43rd Annual Meeting of Infectious Diseases Society of America; San Francisco, October 2005.
13. Harper D for the FUTURE I Investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus-like particle (VLP) vaccine for prevention of cervical dysplasia and external genital lesions (EGL). 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, D.C., 2005.
14. Frazer I. Vaccines for papillomavirus infection. Virus Res 2002; 89: 271-274.
15. Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine 2000; 18: 1051-1058.
16. Goldstone SE, Palefsky JM, Winnett MT, Neefe JR. Activity of HspE7, a novel immunotherapy in patients with anogenital warts. Dis Colon Rectum 2002; 45: 502-507.
17. Lacey CJ, Thompson HS, Monteiro EF et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW in persons with genital warts. J Infect Dis 1999; 179: 612-618.
18. Vandepapeliere P, Barrasso R, Meijer CJ et al. Randomised controlled trial of an adjuvanted human papillomavirus (HPV) type 6, L2E7 vaccine. Infection of external warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005, 192: 2099-2107.
19. Ressing ME, van Driel WJ, Brandt RM et al. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 2000; 23: 255-266.
20. van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV-16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35: 946-952.
21. Muderspach L, Wilczynski S, Roman L et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406-3416.
22. Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papilloma virus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996, 347: 1523-1527.
23. Kaufmann AM, Stern PL, Rankin B et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus HPV-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 2002; 8: 3676-3685.
24. Baldwin PJ, van der Burg SH, Boswell CM et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 2003; 9: 5205-5213.
25. Davidson EJ, Boswell CM, Sehr P et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 2003; 63: 6032-6041.
26. Corona Gutierrez CM, Tinoco A, Navarro T et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN1, CIN 2 and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15: 421-431.
27. Nonn M, Schinz M, Zumbach K et al. Dendritic cell-based tumor vaccine for cervical cancer I: In vitro stimulation with recombinant pretien-pulsed dendritic cells induces specific T cells to HPV 16, E7 or HPV 18, E7. J Cancer Res Clin Oncol 2003, 129: 511-520.
28. Ferrara A, Nonn M, Sehr P et al. Dendritic cell-based tumor vaccine for cervical cancer II: Results of a clinical pilot study in 15 individuals patients. J Cancer Res Clin Oncol 2003; 129: 521-530.
29. Santin AD, Bellone S, Gokden M, Cannon MJ, Parham GP. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 2002; 346: 1752-1753.
30. Smith AMA, Rissel CE, Richters J, Grulich AE, de Visser RO. Sex in Australia: First experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003; 27: 131.
31. Slater PE, Roitman M, Leventhal A, Anis E. Control of rubella in Israel: progress and challenge. Public Health Rev 1996; 24: 183-192.
32. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652-1661.
33. Nolan T, Block SL, Reisinger ICS et al. Comparison of the immunogenicity and tolerability of a prophylactic quadrivalent human papillomavirus (HPV) (types 6, 11, 16, 18) L1 virus like particle (VLP) vaccine in male and female adolescents and young women. 23rd Annual Meeting of the European Society for Paediatric Infectious Diseases (EPSID); 18-20 May 2005, Valencia, Spain.
34. Dubin G, Colau B, Zahaf T, Quint W, Martin M, Jenkins D. Cross-protection against persistent HPV infection, abnormal cytology and CIN associated with HPV-16 and 18 related HPV types by a HPV 16/18, L1 virus-like particle vaccine. 22nd International Papillomavirus Conference and Clinical Workshop; 30 April-6 May 2005, Vancouver, British Columbia, Canada.
35. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
36. Wright JC, Weinstein MC. Gains in life expectancy from medical interventions-standardizing data on outcomes. N Engl J Med 1998; 339: 380-386.
37. White CC, Koplan JP, Orenstein WA. Benefits, risks and costs of immunisation for measles, mumps and rubella. Am J Public Health 1985; 75: 739-744.
38. Hinman AR, Koplan JP. Pertussis and pertussis vaccine: Reanalysis of benefits, risks, and costs. JAMA 1984; 251: 3109-3113.
39. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789.
40. Goldie SJ, Kohli M, Grima D et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615.